DYN
Healthcare BiotechnologyDyne Therapeutics, Inc.
$15.20
-0.62 -3.92% today
Price History
Not enough data
Key Stats
Market Cap
2.84B
Avg Volume
2.72M
EPS
-$3.30
52W High
$27.31
52W Low
$12.43
Div. Yield
0.0%
Analyst Ratings
Buy3
Str Buy
13
Buy
0
Hold
0
Sell
1
Str Sell
Valuation
Forward P/E
-4.56
P/B Ratio
3.59
EV/EBITDA
-4.06
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(81.6%)
Return on Assets
(39.0%)
Liquidity & Leverage
Current Ratio
12.02
Quick Ratio
11.52
Debt / Equity
0.33
Total Cash
898.48M
Total Debt
233.35M
About
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
www.dyne-tx.com